Goldman Sachs Group Inc Esperion Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,307,668 shares of ESPR stock, worth $3.15 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,307,668
Previous 916,011
42.76%
Holding current value
$3.15 Million
Previous $2.03 Million
6.1%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ESPR
# of Institutions
208Shares Held
128MCall Options Held
1.67MPut Options Held
930K-
Wasatch Advisors Inc Salt Lake City, UT23.3MShares$56.3 Million0.19% of portfolio
-
Black Rock Inc. New York, NY14MShares$33.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$31.4 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$24 Million0.28% of portfolio
-
Two Seas Capital LP Rye, NY6.58MShares$15.9 Million3.65% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $160M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...